KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Equity Average (2016 - 2025)

Pfizer (PFE) has disclosed Equity Average for 17 consecutive years, with $89.8 billion as the latest value for Q2 2025.

  • On a quarterly basis, Equity Average changed 0.49% to $89.8 billion in Q2 2025 year-over-year; TTM through Jun 2025 was $89.8 billion, a 0.49% change, with the full-year FY2024 number at $88.7 billion, down 4.16% from a year prior.
  • Equity Average was $89.8 billion for Q2 2025 at Pfizer, roughly flat from $89.4 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $100.3 billion in Q3 2023 to a low of $66.2 billion in Q2 2021.
  • A 5-year average of $87.0 billion and a median of $90.2 billion in 2022 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: grew 23.3% in 2022, then decreased 9.97% in 2024.
  • Pfizer's Equity Average stood at $76.7 billion in 2021, then grew by 23.06% to $94.4 billion in 2022, then decreased by 1.23% to $93.2 billion in 2023, then fell by 3.07% to $90.4 billion in 2024, then decreased by 0.62% to $89.8 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Equity Average are $89.8 billion (Q2 2025), $89.4 billion (Q1 2025), and $90.4 billion (Q4 2024).